CORC

浏览/检索结果: 共4条,第1-4条 帮助

限定条件                    
已选(0)清除 条数/页:   排序方式:
A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE II STUDY TO COMPARE BEVACIZUMAB PLUS SORAFENIB VERSUS SORAFENIB FOR THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT02330783) 会议论文
作者:  Guo, Jun;  Sheng, Xinan;  Chi, Zhihong;  Cui, Chuanliang;  Si, Lu
收藏  |  浏览/下载:5/0  |  提交时间:2019/12/19
Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml 期刊论文
PLOS ONE, 2015, 卷号: 10, 期号: 6
作者:  Chen, Rui;  Huang, Yiran;  Cai, Xiaobing;  Xie, Liping;  He, Dalin
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/19
A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783) 会议论文
作者:  Guo, Jun;  Sheng, Xi Nan;  Chi, Zhihong;  Cui, Chuanliang;  Si, Lu
收藏  |  浏览/下载:2/0  |  提交时间:2019/12/19
Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium 期刊论文
ASIAN JOURNAL OF UROLOGY, 2015, 卷号: 2, 期号: 2
作者:  Chen, Rui;  Xie, Liping;  Cai, Xiaobing;  Huang, Yiran;  Zhou, Liqun
收藏  |  浏览/下载:14/0  |  提交时间:2019/12/19


©版权所有 ©2017 CSpace - Powered by CSpace